AstraZeneca Stock (AZN)

XNGS Alert Compare

Fundamental analysis

AstraZeneca's revenue has grown by 17.2% a year over the last 5 years. The net margin in the last fiscal year was 17.4%. The 52-week high is 22.0% away (close of Nov 20, 2026).

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

At a glance: figures and chart

3 strengths · 0 weaknesses · Fiscal year to Dec 31, 2025
Quality checks from the annual figures and, separately, the position of the price relative to the 200-day line. No overall score.
  • Quality 8 of 8 criteria with data met
  • Growth 7 of 7 criteria with data met
  • Dividend 7 of 7 criteria with data met
  • Financial strength 4 of 6 criteria with data met
Chart position below – position relative to the 200-day line

Strengths well above the threshold

  • Net margin 17.4% Threshold: above 10% · Distance +7.4 pp · Fiscal year to Dec 31, 2025
  • Return on equity 21.0% Threshold: above 15% · Distance +6.0 pp · Fiscal year to Dec 31, 2025
  • Free cash flow margin 20.0% Threshold: above 10% · Distance +10.0 pp · Fiscal year to Dec 31, 2025

Weaknesses well below the threshold

No figure is well below its threshold.

On the radar

  • Position relative to the 200-day line: below (as of Nov 20, 2026)

What we do not know

  • Sector not assigned – no sector median, sector exceptions not checked.

How is this made? · Created on Nov 22, 2026 from fixed rules · not investment advice

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

AstraZeneca is a British-Swedish pharmaceutical company based in Cambridge. Its focus areas are cancer drugs, cardiovascular and metabolic diseases, respiratory diseases and rare diseases through its subsidiary Alexion. Its medicines are sold worldwide. Traded here on the Nasdaq. As of Oct 16, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Cambridge

The company is a global pharmaceutical group that researches, develops, manufactures and markets prescription medicines. Its medicines cover primary care, specialty care and rare diseases. It earns money from product sales and income from collaborations. One focus is oncology with products such as Tagrisso, Imfinzi and Lynparza. The medicines reach patients through a global distribution network and its own supply chains.

Automatically summarized from SEC annual report (20-F, filed Feb 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 19, 2026

What the methods say about AstraZeneca

This symbol belongs to the extended universe: we load daily candles only and show metrics, fundamentals and an overview – chart methods and Elliott analysis are not available for it.

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today −0.6%
  • 7 days −5.5%
  • 30 days +3.5%
  • 1 year −1.7%
Day range (last trading day)
−0.2%Price at 9% of the range+1.8%
52-week range
−12.0%Price at 35% of the range+22.0%
Distance from the all-time high
−18.0%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Chart analysis: trend by timeframe

  1. 1W weekly candles mixed
    • Close above the SMA 200
    • EMA 20 below the EMA 50
    • Highs and lows mixed

    Price above the EMA 20 · above the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles mixed
    • Close below the SMA 200
    • EMA 20 above the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · above the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles not available

    No value on 4 hours (too few or no checked 4-hour candles).

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran stronger than the S&P 500.

vs. S&P 500 · 3 months
stronger
vs. S&P 500 · 6 months
stronger
  • Trend below SMA 200 Price below the 200-day line – below it the long-term trend counts as down; ADX between 20 and 25 – a moderate trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line fell below its signal line in the last 5 trading days.
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility normal Typical daily range (ATR 14) between 2 and 4% of the price – normal.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 5 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
5 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
5 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 4 of 10 years
  • February: higher in 5 of 10 years
  • March: higher in 7 of 10 years
  • April: higher in 6 of 10 years
  • May: higher in 7 of 10 years
  • June: higher in 3 of 10 years
  • July: higher in 7 of 10 years
  • August: higher in 5 of 10 years
  • September: higher in 3 of 10 years
  • October: higher in 6 of 10 years
  • November (current month): higher in 5 of 10 years
  • December: higher in 5 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January4 of 10
February5 of 10
March7 of 10
April6 of 10
May7 of 10
June3 of 10
July7 of 10
August5 of 10
September3 of 10
October6 of 10
November ●5 of 10
December5 of 10

Through October 2026 (last completed month) · from our daily candles

Fundamental analysis

AstraZeneca · amounts in USD

Source: SEC filings, As of Feb 24, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (5 years in a row); free cash flow per share covers it 2.4x.

Years without a cut
at least 5
as far as the data goes
Growth per year (5 yrs)
+2.3%
dividend per share, average per year
Coverage by free cash flow
2.4x
covered from 1.0x

For you first Valuation

Comparable annual figures for the valuation are missing.

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
7 of 7
criteria with data met
Revenue per year (5 y)
+17.2%
EPS per year (5 y)
+21.8%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
8 of 8
criteria with data met
Net margin
17.4%
Cash flow ÷ profit
1.43x
backed from 1.0 · 3 years: 1.58x

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
mixed
daily candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 8 of 8 met

  • met: Gross margin above 40% 81.9%
  • met: Operating margin above 15% 23.4%
  • met: Net margin above 10% 17.4%
  • met: Return on equity above 15% 21.0%
  • met: Free cash flow margin above 10% 20.0%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 42.7%
Gross margin

81.9% Fiscal year 2025

Rank 95 of 100: higher than 95% of 370 peers (All). strong.

Share of revenue left after the direct cost of the products sold.

Operating margin

23.4% Fiscal year 2025

Rank 72 of 100: higher than 72% of 470 peers (All). strong.

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

17.4% Fiscal year 2025

Rank 69 of 100: higher than 69% of 584 peers (All). strong.

Profit after all costs, interest and taxes divided by revenue.

Return on equity

21.0% Fiscal year 2025

Rank 70 of 100: higher than 70% of 544 peers (All). strong.

Net income divided by equity at fiscal year end.

Return on assets

9.0% Fiscal year 2025 (total assets at year end)

Rank 72 of 100: higher than 72% of 594 peers (All). strong.

Net income divided by total assets at fiscal year end.

Equity ratio

42.7% Fiscal year 2025

Rank 59 of 100: higher than 59% of 595 peers (All). medium.

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

20.0% Fiscal year 2025

Rank 76 of 100: higher than 76% of 465 peers (All). strong.

Free cash flow divided by revenue.

Free cash flow

11.8B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 7 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +9.8%
  • met: Over 5 years, revenue grew by more than 5% per year +17.2%
  • met: Over 10 years, revenue grew by more than 5% per year +9.0%
  • met: Over 3 years, EPS grew by more than 5% per year +45.8%
  • met: Over 5 years, EPS grew by more than 5% per year +21.8%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +8.6%
Revenue growth 3 years

+9.8% per year

Rank 67 of 100: higher than 67% of 578 peers (All). strong.

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+17.2% per year

Rank 78 of 100: higher than 78% of 549 peers (All). strong.

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+9.0% per year

Rank 66 of 100: higher than 66% of 412 peers (All). medium.

Average growth per year over 10 fiscal years.

EPS growth 3 years

+45.8% per year

Rank 92 of 100: higher than 92% of 437 peers (All). strong.

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+21.8% per year

Rank 77 of 100: higher than 77% of 399 peers (All). strong.

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+11.4% per year

Rank 57 of 100: higher than 57% of 375 peers (All). medium.

Growth of earnings per share per year, adjusted for stock splits.

Dividend 7 of 7 met

  • met: Pays a dividend 3.13 USD
  • met: Payout ratio at most 60% of earnings 48%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +2.3%
  • met: Free cash flow per share covers the dividend 2.4x
  • met: Dividends paid over the last 5 years covered by free cash flow 50% of free cash flow
Payout ratio

48% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+2.3% per year

Rank 16 of 100: higher than 16% of 321 peers (All). weak.

Growth of the dividend per share per year.

Free cash flow coverage

2.4x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 4 of 6 met

  • met: Piotroski F-Score at least 7 of 9 9 of 9
  • met: Long-term debt no higher than equity 0.51
  • not met: Current assets cover current liabilities 0.94
  • met: Positive equity 48.7B USD
  • not met: In 5 years, share count up by at most 5% +19.0%
  • met: Free cash flow positive in the last fiscal year 11.8B USD
Piotroski F-Score

9 of 9 Fiscal year 2025

Rank 98 of 100: higher than 98% of 310 peers (All). strong.

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.51 at fiscal year end

Rank 61 of 100: lower than 61% of 486 peers (All). medium.

Long-term financial debt divided by equity.

Liquidity (current ratio)

0.94 at fiscal year end

Rank 22 of 100: higher than 22% of 513 peers (All). weak.

Current assets divided by current liabilities.

Change in share count

+19.0% in 5 years

Rank 14 of 100: lower than 14% of 507 peers (All). weak.

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

20-F filer (foreign company): amounts in the reporting currency, no price-based criteria.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+17.2% per year).
  • Light green: Net income (total) grew over 5 years (+26.2% per year); per share +21.8% per year.
  • Light green: Net margin 17.4%.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 23.0B USD · Net income 3.5B USD · Net margin 15.2%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 22.5B USD · Net income 3.0B USD · Net margin 13.4%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 22.1B USD · Net income 2.2B USD · Net margin 9.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 24.4B USD · Net income 1.3B USD · Net margin 5.5%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 26.6B USD · Net income 3.2B USD · Net margin 12.0%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 37.4B USD · Net income 112.0M USD · Net margin 0.3%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 44.4B USD · Net income 3.3B USD · Net margin 7.4%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 45.8B USD · Net income 6.0B USD · Net margin 13.0%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 54.1B USD · Net income 7.0B USD · Net margin 13.0%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 58.7B USD · Net income 10.2B USD · Net margin 17.4%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 58.7B USD · Net income 10.2B USD · Net margin 17.4%

How has it gone since the last annual report?

Trailing 12 months and quarters

This company files only annual reports with the SEC (20-F) – there are no trailing 12-month or quarterly figures for it.

Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
1.43x
backed from 1.0 · 3 years: 1.58x
Interest coverage
8.1x
well covered from 5 · 3 years: 6.3x
Tax rate
17.5%
for information only · 3 years: 17.0%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 14.6B USD ÷ Net income 10.2B USD = 1.43x
  • Operating income 13.7B USD ÷ Interest expense 1.7B USD = 8.1x
  • Taxes 2.2B USD ÷ profit before tax 12.4B USD = 17.5%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20251.43x8.1x17.5%
20241.69x5.7x19.0%
20231.74x5.0x13.6%
20222.98x2.8x−31.7%
2021over 10x0.8x–

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and 3 years with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
3 of 10
revenue below the prior year
Net margin range
17.1 percentage points
from 0.3% to 17.4%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+8.6%17.4%
2024+18.0%13.0%
2023+3.3%13.0%
2022+18.5%7.4%
2021+40.6%0.3%
2020+9.2%12.0%
2019+10.4%5.5%
2018−1.7%9.8%
2017−2.3%13.4%
2016−6.9%15.2%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 81.9 USD gross profit, 23.4 USD operating income and 17.4 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue58.7B USD100.0%
Gross profit48.1B USD81.9%
Cost of revenue10.6B USD18.1%
Operating income13.7B USD23.4%
Research & development14.2B USD24.2%
Other operating expenses20.1B USD34.3%
Net income10.2B USD17.4%
Interest expense1.7B USD2.9%
Taxes & other (net)1.8B USD3.1%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from 19.4% to 23.4%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 82.1% · Operating margin 21.3% · Net margin 15.2%
  2. Fiscal year 2017: Gross margin 80.8% · Operating margin 16.4% · Net margin 13.4%
  3. Fiscal year 2018: Gross margin 77.7% · Operating margin 15.3% · Net margin 9.8%
  4. Fiscal year 2019: Gross margin 79.8% · Operating margin 12.0% · Net margin 5.5%
  5. Fiscal year 2020: Gross margin 80.1% · Operating margin 19.4% · Net margin 12.0%
  6. Fiscal year 2021: Gross margin 66.8% · Operating margin 2.8% · Net margin 0.3%
  7. Fiscal year 2022: Gross margin 72.1% · Operating margin 8.5% · Net margin 7.4%
  8. Fiscal year 2023: Gross margin 82.0% · Operating margin 17.9% · Net margin 13.0%
  9. Fiscal year 2024: Gross margin 81.1% · Operating margin 18.5% · Net margin 13.0%
  10. Fiscal year 2025: Gross margin 81.9% · Operating margin 23.4% · Net margin 17.4%

Returns

Return on equity stayed roughly the same in 5 years (21.0%).

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 23.6% · Return on assets 5.6%
  2. Fiscal year 2017: Return on equity 20.1% · Return on assets 4.7%
  3. Fiscal year 2018: Return on equity 17.3% · Return on assets 3.6%
  4. Fiscal year 2019: Return on equity 10.2% · Return on assets 2.2%
  5. Fiscal year 2020: Return on equity 20.5% · Return on assets 4.8%
  6. Fiscal year 2021: Return on equity 0.3% · Return on assets 0.1%
  7. Fiscal year 2022: Return on equity 8.9% · Return on assets 3.4%
  8. Fiscal year 2023: Return on equity 15.2% · Return on assets 5.9%
  9. Fiscal year 2024: Return on equity 17.2% · Return on assets 6.8%
  10. Fiscal year 2025: Return on equity 21.0% · Return on assets 9.0%

Equity and long-term debt

The equity ratio rose in 5 years from 23.4% to 42.7%.

Equity in USD Long-term debt not shown: the 20-F filing has no tag for bonds.
  1. Fiscal year 2016: Equity 14.9B USD
  2. Fiscal year 2017: Equity 15.0B USD
  3. Fiscal year 2018: Equity 12.5B USD
  4. Fiscal year 2019: Equity 13.1B USD
  5. Fiscal year 2020: Equity 15.6B USD
  6. Fiscal year 2021: Equity 39.3B USD
  7. Fiscal year 2022: Equity 37.0B USD
  8. Fiscal year 2023: Equity 39.1B USD
  9. Fiscal year 2024: Equity 40.8B USD
  10. Fiscal year 2025: Equity 48.7B USD

Liquidity (current ratio)

The current ratio stayed roughly the same in 5 years (0.94).

Current ratio
  1. Fiscal year 2016: Current ratio 0.87
  2. Fiscal year 2017: Current ratio 0.80
  3. Fiscal year 2018: Current ratio 0.96
  4. Fiscal year 2019: Current ratio 0.86
  5. Fiscal year 2020: Current ratio 0.96
  6. Fiscal year 2021: Current ratio 1.16
  7. Fiscal year 2022: Current ratio 0.86
  8. Fiscal year 2023: Current ratio 0.82
  9. Fiscal year 2024: Current ratio 0.93
  10. Fiscal year 2025: Current ratio 0.94

Cash flow

Free cash flow rose in 5 years from 3.8B USD to 11.8B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 4.1B USD · Capital expenditure 1.4B USD · Free cash flow 2.7B USD
  2. Fiscal year 2017: Operating cash flow 3.6B USD · Capital expenditure 1.3B USD · Free cash flow 2.3B USD
  3. Fiscal year 2018: Operating cash flow 2.6B USD · Capital expenditure 1.0B USD · Free cash flow 1.6B USD
  4. Fiscal year 2019: Operating cash flow 3.0B USD · Capital expenditure 979.0M USD · Free cash flow 2.0B USD
  5. Fiscal year 2020: Operating cash flow 4.8B USD · Capital expenditure 961.0M USD · Free cash flow 3.8B USD
  6. Fiscal year 2021: Operating cash flow 6.0B USD · Capital expenditure 1.1B USD · Free cash flow 4.9B USD
  7. Fiscal year 2022: Operating cash flow 9.8B USD · Capital expenditure 1.1B USD · Free cash flow 8.7B USD
  8. Fiscal year 2023: Operating cash flow 10.3B USD · Capital expenditure 1.4B USD · Free cash flow 9.0B USD
  9. Fiscal year 2024: Operating cash flow 11.9B USD · Capital expenditure 1.9B USD · Free cash flow 9.9B USD
  10. Fiscal year 2025: Operating cash flow 14.6B USD · Capital expenditure 2.8B USD · Free cash flow 11.8B USD

Share count

The share count rose in 5 years by 19.0% – more new shares were issued than repurchased (dilution).

Average share count
  1. Fiscal year 2016: Average share count 1.3B
  2. Fiscal year 2017: Average share count 1.3B
  3. Fiscal year 2018: Average share count 1.3B
  4. Fiscal year 2019: Average share count 1.3B
  5. Fiscal year 2020: Average share count 1.3B
  6. Fiscal year 2021: Average share count 1.4B
  7. Fiscal year 2022: Average share count 1.6B
  8. Fiscal year 2023: Average share count 1.6B
  9. Fiscal year 2024: Average share count 1.6B
  10. Fiscal year 2025: Average share count 1.6B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Dividend per share

The dividend per share rose in 5 years from 2.80 USD to 3.13 USD.

AZN USD per share
  1. Fiscal year 2016: AZN not available
  2. Fiscal year 2017: AZN not available
  3. Fiscal year 2018: AZN not available
  4. Fiscal year 2019: AZN not available
  5. Fiscal year 2020: AZN 2.80 USD
  6. Fiscal year 2021: AZN 2.80 USD
  7. Fiscal year 2022: AZN 2.90 USD
  8. Fiscal year 2023: AZN 2.90 USD
  9. Fiscal year 2024: AZN 2.97 USD
  10. Fiscal year 2025: AZN 3.13 USD

Payout ratio (earnings)

The payout ratio fell in 5 years from 114.8% to 47.9%.

AZN
  1. Fiscal year 2016: AZN not available
  2. Fiscal year 2017: AZN not available
  3. Fiscal year 2018: AZN not available
  4. Fiscal year 2019: AZN not available
  5. Fiscal year 2020: AZN 114.8%
  6. Fiscal year 2021: AZN not available
  7. Fiscal year 2022: AZN 137.4%
  8. Fiscal year 2023: AZN 76.1%
  9. Fiscal year 2024: AZN 66.0%
  10. Fiscal year 2025: AZN 47.9%

Payout ratio (free cash flow)

The payout ratio (free cash flow) fell in 5 years from 93.1% to 42.3%.

AZN
  1. Fiscal year 2016: AZN not available
  2. Fiscal year 2017: AZN not available
  3. Fiscal year 2018: AZN not available
  4. Fiscal year 2019: AZN not available
  5. Fiscal year 2020: AZN 93.1%
  6. Fiscal year 2021: AZN 79.1%
  7. Fiscal year 2022: AZN 50.1%
  8. Fiscal year 2023: AZN 49.9%
  9. Fiscal year 2024: AZN 46.6%
  10. Fiscal year 2025: AZN 42.3%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (5 years in a row); free cash flow per share covers it 2.4x.

Years without a cut
at least 5
as far as the data goes
Growth per year (5 yrs)
+2.3%
dividend per share, average per year
Coverage by free cash flow
2.4x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 2.80 USD → fiscal year 2025 3.13 USD = +2.3% per year
  • Free cash flow per share 7.53 USD ÷ dividend per share 3.13 USD = 2.4x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
3.13 USD · Fiscal year 2025
Dividend growth per year
3 y +2.6%5 y +2.3%10 y –
Payout ratio
of earnings 48% of free cash flow 42%
To shareholders (5 years)
23.1B USD 3% through repurchases
Share count over 5 years
+19.0% more shares – dilution

Dividend per share

The dividend per share rose in 5 years from 2.80 USD to 3.13 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share not available
  2. Fiscal year 2017: Dividend per share not available
  3. Fiscal year 2018: Dividend per share not available
  4. Fiscal year 2019: Dividend per share not available
  5. Fiscal year 2020: Dividend per share 2.80 USD
  6. Fiscal year 2021: Dividend per share 2.80 USD
  7. Fiscal year 2022: Dividend per share 2.90 USD
  8. Fiscal year 2023: Dividend per share 2.90 USD
  9. Fiscal year 2024: Dividend per share 2.97 USD
  10. Fiscal year 2025: Dividend per share 3.13 USD

Payout ratios

The payout ratio fell in 5 years from 114.8% to 47.9%.

Payout ratio (earnings)Payout ratio (free cash flow) Ratios above 500% hidden (earnings or free cash flow close to zero).
  1. Fiscal year 2016: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  2. Fiscal year 2017: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  3. Fiscal year 2018: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  4. Fiscal year 2019: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  5. Fiscal year 2020: Payout ratio (earnings) 114.8% · Payout ratio (free cash flow) 93.1%
  6. Fiscal year 2021: Payout ratio (earnings) not available · Payout ratio (free cash flow) 79.1%
  7. Fiscal year 2022: Payout ratio (earnings) 137.4% · Payout ratio (free cash flow) 50.1%
  8. Fiscal year 2023: Payout ratio (earnings) 76.1% · Payout ratio (free cash flow) 49.9%
  9. Fiscal year 2024: Payout ratio (earnings) 66.0% · Payout ratio (free cash flow) 46.6%
  10. Fiscal year 2025: Payout ratio (earnings) 47.9% · Payout ratio (free cash flow) 42.3%

What goes back to shareholders

Over 5 years, 23.1B USD went back to shareholders, 3% of it through share repurchases. That is 52% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 2.7B USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 2.3B USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 1.6B USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 2.0B USD
  5. Fiscal year 2020: Dividends paid 3.6B USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 3.8B USD
  6. Fiscal year 2021: Dividends paid 3.9B USD · Share repurchases 149.0M USD · New shares issued (including employee plans) not available · Free cash flow 4.9B USD
  7. Fiscal year 2022: Dividends paid 4.4B USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 8.7B USD
  8. Fiscal year 2023: Dividends paid 4.5B USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 9.0B USD
  9. Fiscal year 2024: Dividends paid 4.6B USD · Share repurchases 81.0M USD · New shares issued (including employee plans) not available · Free cash flow 9.9B USD
  10. Fiscal year 2025: Dividends paid 5.0B USD · Share repurchases 521.0M USD · New shares issued (including employee plans) not available · Free cash flow 11.8B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

20-F filer or other currency: earnings per share and share count do not reliably match the price of the US listing (ADR) – so there is no price-based valuation here.

Key figures with traffic lights

Each light follows a simple, disclosed rule. This symbol has no sector assignment – lights with a sector comparison stay gray or use only the basic rule.

Revenue growth

Light green: growing

+17.2% per year, last 5 years

What does this mean? Revenue: over 5 years it grew by 17.2% per year on average. Comparable values for a sector comparison are missing.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: growing

+26.2% per year, last 5 years

per share: +21.8% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 26.2% per year on average. Comparable values for a sector comparison are missing.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: Gain

17.4% last fiscal year

What does this mean? Of every 100 USD in revenue, 17.41 USD remained as profit. Comparable values for a sector comparison are missing.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light gray: no comparison

0.61 latest balance sheet

What does this mean? For every 1 USD of equity there is 0.61 USD of financial debt. Without a sector comparison this is hard to put into context.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

48% Dividend / earnings per share

What does this mean? Of every 1 USD of earnings per share, 0.48 USD went to shareholders as a dividend. The rest stays in the company.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
58.7B USD
Revenue vs. prior year
+8.6%
Net income (FY)
10.2B USD
Net income vs. prior year
+45.3%
EPS (FY)
6.54 USD
Superinvestors holding
3 of 26
Fiscal year to Dec 31, 2025 · 20-F filed Feb 24, 2026 · Balance sheet Dec 31, 2025 (filed Feb 24, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 58.7B10.2B 17.4% 6.54 3.13 48%
2024Dec 31, 2024 54.1B7.0B 13.0% 4.50 2.97 66%
2023Dec 31, 2023 45.8B6.0B 13.0% 3.81 2.90 76%
2022Dec 31, 2022 44.4B3.3B 7.4% 2.11 2.90 137%
2021Dec 31, 2021 37.4B112.0M 0.3% 0.08 2.80 3,500%
2020Dec 31, 2020 26.6B3.2B 12.0% 2.44 2.80 115%
2019Dec 31, 2019 24.4B1.3B 5.5% 1.03 – –
2018Dec 31, 2018 22.1B2.2B 9.8% 1.70 – –
2017Dec 31, 2017 22.5B3.0B 13.4% 2.37 – –
2016Dec 31, 2016 23.0B3.5B 15.2% 2.76 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/25Jun 30, 2025 14.5B2.5B 16.9% 1.57 – –
Q2/24Jun 30, 2024 12.9B1.9B 14.9% 1.24 – –
Q2/23Jun 30, 2023 11.4B1.8B 15.9% 1.17 – –
Q2/22Jun 30, 2022 10.8B360.0M 3.3% 0.23 – –
Q2/21Jun 30, 2021 8.2B550.0M 6.7% 0.42 – –
Q1/21Mar 31, 2021 7.3B– – – – –
Q4/20Dec 31, 2020 7.0B– – – – –
Q3/20Sep 30, 2020 6.5B– – – – –
Q2/20Jun 30, 2020 6.3B756.0M 12.0% 0.58 – –
Q1/20Mar 31, 2020 6.3B– – – – –
Q4/19Dec 31, 2019 6.3B– – – – –
Q3/19Sep 30, 2019 6.1B– – – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $3.2K1 person $00 people +$3.2K
12 months $3.2K1 person $2.2M1 person −$2.2M

Latest transactions

  • Aug 8, 2026 Sharma Mani Officer Open-market purchase 20 shares · $3.2K · SEC
  • May 20, 2026 Sharma Mani Officer Open-market sale 11,893 shares · $2.2M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold AstraZeneca?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in AstraZeneca, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Steve Cohen Point72 Asset Management 0.5% +134.4% increased Q3 2026
Renaissance Technologies < 0.1% new Q3 2026
Bridgewater Associates < 0.1% new Q3 2026

Sold out in the latest quarter: Paul Tudor Jones.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Other stocks

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on AZN yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: AZN

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close